Geode Capital Management LLC Buys 154,848 Shares of Standard BioTools Inc. (NASDAQ:LAB)

Geode Capital Management LLC boosted its stake in shares of Standard BioTools Inc. (NASDAQ:LAB) by 2.3% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 6,949,717 shares of the company’s stock after acquiring an additional 154,848 shares during the quarter. Geode Capital Management LLC owned approximately 1.87% of Standard BioTools worth $13,415,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Arizona State Retirement System grew its holdings in Standard BioTools by 16.6% during the 2nd quarter. Arizona State Retirement System now owns 69,596 shares of the company’s stock worth $123,000 after acquiring an additional 9,933 shares during the last quarter. XTX Topco Ltd grew its holdings in Standard BioTools by 38.2% during the 2nd quarter. XTX Topco Ltd now owns 35,965 shares of the company’s stock worth $64,000 after acquiring an additional 9,947 shares during the last quarter. Victory Capital Management Inc. grew its holdings in Standard BioTools by 27.3% during the 2nd quarter. Victory Capital Management Inc. now owns 46,967 shares of the company’s stock worth $83,000 after acquiring an additional 10,067 shares during the last quarter. Wolverine Trading LLC bought a new stake in Standard BioTools during the 3rd quarter worth about $27,000. Finally, Nisa Investment Advisors LLC boosted its stake in shares of Standard BioTools by 433.8% in the 3rd quarter. Nisa Investment Advisors LLC now owns 18,128 shares of the company’s stock valued at $35,000 after purchasing an additional 14,732 shares during the last quarter. Institutional investors own 53.74% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, TD Cowen reduced their target price on shares of Standard BioTools from $2.75 to $2.50 and set a “buy” rating on the stock in a research note on Thursday, October 31st.

Standard BioTools Trading Down 2.7 %

Shares of NASDAQ LAB opened at $1.77 on Tuesday. The firm has a market capitalization of $658.90 million, a PE ratio of -2.49 and a beta of 1.61. Standard BioTools Inc. has a 1 year low of $1.21 and a 1 year high of $3.04. The firm’s 50-day moving average is $1.87 and its 200-day moving average is $1.91.

Standard BioTools Company Profile

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.